Published in Drug Metab Pharmacokinet on June 01, 2007
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol (2009) 1.53
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med (2009) 1.04
Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J (2010) 1.01
Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int J Pharm (2011) 1.01
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One (2012) 0.94
Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res (2009) 0.90
Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells. Int J Nanomedicine (2013) 0.90
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine (2012) 0.90
Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol (2009) 0.88
Therapeutic RNA manipulation in liver disease. Hepatology (2010) 0.85
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. Acta Naturae (2013) 0.83
MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr Drug Targets (2010) 0.81
In vivo siRNA delivery of Keap1 modulates death and survival signaling pathways and attenuates concanavalin-A-induced acute liver injury in mice. Dis Model Mech (2014) 0.80
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J Histochem Cytochem (2013) 0.79
Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts. Int J Cancer (2011) 0.79
Non-small cell lung carcinoma therapy using mTOR-siRNA. Int J Clin Exp Pathol (2012) 0.79
Ethical perspectives on RNA interference therapeutics. Int J Med Sci (2008) 0.78
Ethanol treatment a Non-extrusion method for asymmetric liposome size optimization. Daru (2013) 0.77
Enhanced delivery of PEAL nanoparticles with ultrasound targeted microbubble destruction mediated siRNA transfection in human MCF-7/S and MCF-7/ADR cells in vitro. Int J Nanomedicine (2015) 0.77
Luminescent proteins for high-speed single-cell and whole-body imaging. Nat Commun (2012) 2.24
piggyBac transposon-mediated long-term gene expression in mice. Mol Ther (2010) 1.33
Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release (2006) 1.15
Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs (2010) 1.14
Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci (2008) 1.13
Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials (2006) 1.07
Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev (2009) 1.07
Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther (2006) 1.03
Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther (2003) 1.01
PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release (2006) 0.99
Creation of pure nanodrugs and their anticancer properties. Angew Chem Int Ed Engl (2012) 0.99
Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull (2002) 0.96
PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med (2006) 0.96
Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochem Biophys Res Commun (2008) 0.96
Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun (2002) 0.96
Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release (2007) 0.95
Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin Exp Metastasis (2004) 0.95
Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin Drug Deliv (2006) 0.93
Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev (2012) 0.93
Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. J Control Release (2006) 0.93
Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J Pharmacol Exp Ther (2005) 0.92
Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm (2006) 0.91
Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating blood in mice. Transplantation (2008) 0.91
Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J Control Release (2009) 0.91
Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug Chem (2010) 0.91
Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release (2009) 0.91
Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J Control Release (2006) 0.90
Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer (2002) 0.89
Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol (2008) 0.88
Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst (2002) 0.88
Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure. Hum Gene Ther (2010) 0.88
Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. Eur J Pharm Sci (2003) 0.88
Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci (2005) 0.88
Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther (2003) 0.88
Mechanistic and empirical modeling of skin permeation of drugs. Adv Drug Deliv Rev (2003) 0.88
Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release (2006) 0.88
SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin Exp Metastasis (2008) 0.87
Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. J Control Release (2009) 0.87
Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. J Control Release (2009) 0.87
Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials (2010) 0.87
Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release (2005) 0.87
Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. J Control Release (2009) 0.87
Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. J Pharmacol Exp Ther (2002) 0.87
In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet (2004) 0.86
Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res (2002) 0.86
Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release (2005) 0.86
Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release (2004) 0.86
Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J Pharmacol Exp Ther (2006) 0.86
Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm (2005) 0.86
Determination of matrine in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. Talanta (2003) 0.86
Photothermic regulation of gene expression triggered by laser-induced carbon nanohorns. Proc Natl Acad Sci U S A (2012) 0.85
Photodynamic and photothermal effects of semiconducting and metallic-enriched single-walled carbon nanotubes. J Am Chem Soc (2012) 0.85
Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett (2009) 0.85
Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials (2007) 0.85
Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. Int J Pharm (2002) 0.85
Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res (2004) 0.85
Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J Control Release (2007) 0.84
In vitro evaluation of inhibitory effect of nuclear factor-kappaB activity by small interfering RNA on pro-tumor characteristics of M2-like macrophages. Biol Pharm Bull (2013) 0.84
Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm (2009) 0.84
Mannosylated semiconductor quantum dots for the labeling of macrophages. J Control Release (2007) 0.84
Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res (2010) 0.84
Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS One (2013) 0.84
Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release (2009) 0.83
Development of lysine-histidine dendron modified chitosan for improving transfection efficiency in HEK293 cells. J Control Release (2011) 0.83
Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm (2003) 0.83
Enhanced hepatocyte-selective in vivo gene expression by stabilized galactosylated liposome/plasmid DNA complex using sodium chloride for complex formation. Mol Ther (2004) 0.83
Improvement of insulin resistance by removal of systemic hydrogen peroxide by PEGylated catalase in obese mice. Mol Pharm (2010) 0.83
Inhibition of cancer cell growth by GRP78 siRNA lipoplex via activation of unfolded protein response. Biol Pharm Bull (2014) 0.82
Analysis of hepatic disposition of galactosylated cationic liposome/plasmid DNA complexes in perfused rat liver. Pharm Res (2003) 0.82
Analysis of in vivo nuclear factor-kappaB activation during liver inflammation in mice: prevention by catalase delivery. Mol Pharmacol (2006) 0.82
Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cells. Biomaterials (2011) 0.82
Insertion of nuclear factor-kappaB binding sequence into plasmid DNA for increased transgene expression in colon carcinoma cells. J Biotechnol (2007) 0.82
Use of mannosylated cationic liposomes/ immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. J Gene Med (2008) 0.82
Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target (2006) 0.82
Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in mice. J Control Release (2013) 0.82
Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier. Mol Pharm (2011) 0.82
Efficient suppression of murine intracellular adhesion molecule-1 using ultrasound-responsive and mannose-modified lipoplexes inhibits acute hepatic inflammation. Hepatology (2012) 0.82
Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice. J Drug Target (2005) 0.82
Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun (2004) 0.81
Pressure-mediated transfection of murine spleen and liver. Hum Gene Ther (2009) 0.81
Immunostimulatory characteristics induced by linear polyethyleneimine-plasmid DNA complexes in cultured macrophages. Hum Gene Ther (2009) 0.81
Hydrogen peroxide-mediated nuclear factor kappaB activation in both liver and tumor cells during initial stages of hepatic metastasis. Cancer Sci (2008) 0.81
Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release (2007) 0.81
Interaction with blood components plays a crucial role in asialoglycoprotein receptor-mediated in vivo gene transfer by galactosylated lipoplex. J Pharmacol Exp Ther (2005) 0.81
Evaluation of osteoclastogenesis via NFκB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cytokine production from primary cultured macrophages. Pharm Res (2011) 0.81
Use of lipoplex-induced nuclear factor-kappaB activation to enhance transgene expression by lipoplex in mouse lung. J Gene Med (2006) 0.81
Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med (2006) 0.81
Glycosylated cationic liposomes for cell-selective gene delivery. Crit Rev Ther Drug Carrier Syst (2002) 0.81
Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release (2006) 0.81
Cationic charge-dependent hepatic delivery of amidated serum albumin. J Control Release (2005) 0.81
Physicochemical, tissue distribution, and vasodilation characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo. J Pharm Sci (2004) 0.81
Exclusive photothermal heat generation by a gadolinium bis(naphthalocyanine) complex and inclusion into modified high-density lipoprotein nanocarriers for therapeutic applications. ACS Nano (2013) 0.80
The potential role of fucosylated cationic liposome/NFkappaB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials (2006) 0.80
Development of nitric oxide donors for the treatment of cardiovascular diseases. Cardiovasc Hematol Agents Med Chem (2007) 0.80
Tissue-specific characteristics of in vivo electric gene: transfer by tissue and intravenous injection of plasmid DNA. Pharm Res (2005) 0.80
Pharmacokinetics of plasmid DNA-based non-viral gene medicine. Adv Genet (2005) 0.80
Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release (2002) 0.80
Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm (2004) 0.80
Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer. Gene (2011) 0.80
Quantitative structure/property relationship analysis of Caco-2 permeability using a genetic algorithm-based partial least squares method. J Pharm Sci (2002) 0.80